ERBB2 and breast cancer: We profiled the epigenetic landscape using chromatin accessibility analysis of 42 prospectively collected BC samples, including 35 ER + /HER2 − and 7 triple-negative breast tumours (Table 1, JFCR–BRCA cohort).